Table 2.
Cellular ratio, measurement of anti-nucleoprotein IgG levels and time from the third dose administration of eight people living with HIV (PLWH), who received a fourth anti-SARS-CoV-2 mRNA vaccine dose. SD: standard deviation.
| PLWH | CD4/CD8 Ratio | Anti-N IgG * T0 Pre-Fourth Dose |
Anti-N IgG * T +7 Days |
Anti-N IgG * T +1 Month |
Anti-N IgG * T +2 Months |
Time between the Third and Fourth Vaccine Doses (Days) |
|---|---|---|---|---|---|---|
| V1 | 1.7 | 0.01 | 0.01 | 0.01 | 0.01 | 167 |
| V2 | 1 | 0.02 | 0.02 | 0.02 | 0.03 | 160 |
| V3 | 0.4 | 0.08 | 0.06 | 0.02 | 0.02 | 107 |
| V4 | 1 | 0.01 | 0.06 | 0.02 | 0.01 | 108 |
| V5 | 0.4 | 0.08 | 0.08 | 0.08 | 0.07 | 101 |
| V6 | 0.8 | 0.56 | 0.56 | 0.50 | 0.56 | 94 |
| V7 | 0.1 | 0.04 | 0.03 | 0.03 | 3.38 | 117 |
| V8 | 0.7 | 0.92 | 0.64 | 0.41 | 8.14 | 94 |
| Mean SD |
0.8 0.5 |
0.2 0.3 |
0.2 0.3 |
0.1 0.2 |
1.5 2.9 |
119 29 |
* index, cut-off = 1.4.